Wall Street analysts expect that Merck & Co., Inc. (NYSE:MRK) will report earnings of $1.14 per share for the current quarter, according to Zacks. Two analysts have provided estimates for Merck & Co., Inc.’s earnings. The lowest EPS estimate is $1.12 and the highest is $1.14. Merck & Co., Inc. reported earnings of $1.04 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 9.6%. The business is scheduled to announce its next quarterly earnings report on Friday, February 7th.
On average, analysts expect that Merck & Co., Inc. will report full-year earnings of $5.15 per share for the current financial year, with EPS estimates ranging from $5.12 to $5.17. For the next financial year, analysts expect that the firm will post earnings of $5.49 per share, with EPS estimates ranging from $5.35 to $5.80. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that follow Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The firm had revenue of $12.40 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same period in the prior year, the business earned $1.19 EPS. The business’s revenue for the quarter was up 14.9% on a year-over-year basis.
MRK has been the subject of several research reports. Mizuho raised their price target on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Svb Leerink began coverage on shares of Merck & Co., Inc. in a research note on Friday, August 16th. They issued an “outperform” rating and a $103.00 price objective on the stock. Societe Generale set a $105.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Bank of America started coverage on shares of Merck & Co., Inc. in a report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 price target on the stock. Finally, JPMorgan Chase & Co. set a $96.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $95.47.
Shares of MRK opened at $87.04 on Friday. The company has a market capitalization of $221.96 billion, a price-to-earnings ratio of 20.06, a P/E/G ratio of 1.89 and a beta of 0.52. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $87.99. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.26 and a quick ratio of 0.98. The business’s 50-day moving average is $84.70 and its 200-day moving average is $83.71.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 8th. Investors of record on Monday, December 16th will be paid a $0.61 dividend. This represents a $2.44 annualized dividend and a dividend yield of 2.80%. The ex-dividend date is Friday, December 13th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.55. Merck & Co., Inc.’s payout ratio is presently 50.69%.
A number of institutional investors have recently bought and sold shares of MRK. Webster Bank N. A. increased its stake in Merck & Co., Inc. by 7.3% during the second quarter. Webster Bank N. A. now owns 29,607 shares of the company’s stock valued at $2,483,000 after acquiring an additional 2,004 shares during the period. Bogart Wealth LLC increased its position in shares of Merck & Co., Inc. by 10.6% during the second quarter. Bogart Wealth LLC now owns 33,173 shares of the company’s stock valued at $2,781,000 after purchasing an additional 3,192 shares during the period. Northstar Group Inc. increased its position in shares of Merck & Co., Inc. by 1.1% during the second quarter. Northstar Group Inc. now owns 16,960 shares of the company’s stock valued at $1,422,000 after purchasing an additional 192 shares during the period. AdvisorNet Financial Inc raised its stake in shares of Merck & Co., Inc. by 0.8% in the second quarter. AdvisorNet Financial Inc now owns 44,029 shares of the company’s stock valued at $3,692,000 after purchasing an additional 350 shares in the last quarter. Finally, Forte Capital LLC ADV raised its stake in shares of Merck & Co., Inc. by 6.1% in the second quarter. Forte Capital LLC ADV now owns 28,861 shares of the company’s stock valued at $2,420,000 after purchasing an additional 1,647 shares in the last quarter. 74.53% of the stock is currently owned by hedge funds and other institutional investors.
Merck & Co., Inc. Company Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
See Also: Blockchain
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.